Atıf İçin Kopyala
KAYA E., SIKKA S., Oral D., OZAKCA I., GUR S.
CURRENT DRUG TARGETS, cilt.19, sa.6, ss.602-612, 2018 (SCI-Expanded)
-
Yayın Türü:
Makale / Derleme
-
Cilt numarası:
19
Sayı:
6
-
Basım Tarihi:
2018
-
Doi Numarası:
10.2174/1389450118666170120165554
-
Dergi Adı:
CURRENT DRUG TARGETS
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus
-
Sayfa Sayıları:
ss.602-612
-
Anahtar Kelimeler:
beta(3)-adrenoceptor, drug effect, male urogenital system, mirabegron, voiding, overactive bladder, BLADDER SMOOTH-MUSCLE, BETA-ADRENOCEPTOR AGONISTS, INDUCED CONTRACTILE RESPONSES, ACTIVE-CONTROLLED PHASE-3, RANDOMIZED DOUBLE-BLIND, ASSESS 12-MONTH SAFETY, ADD-ON TREATMENT, OVERACTIVE BLADDER, URINARY-BLADDER, RECEPTOR AGONIST
-
Çukurova Üniversitesi Adresli:
Evet
Özet
The sympathetic nervous system is one component of the nervous regulatory system of the physiological function of the lower genitourinary tract. Our knowledge on the role of this sympathetic system has advanced during the last decade due to the characterization of beta(3)-adrenoceptors (beta(3)-ARs) in the urogenital system. This review focuses on the pharmacological and molecular evidence supporting the functional roles of beta(3)-AR in male genitourinary tissues of various species.